Related Experiment Videos
Effect of immunization with attenuated Mycobacterium bovis (BCG) on experimental herpetic keratitis
Abstract:
Mycobacterium bovis (BCG, Pasteur strain) was injected intraperitoneally into guinea pigs and rabbits on the 19th and 5th days prior to the intracorneal inoculation of Herpesvirus hominis. During a three-day and nine-day observation period, respectively, the BCG had no significant effect on the clinical course of the herpetic keratitis and no effect on the titer of virus present in the infected corneas.
Insights
Bacillus Calmette-Guérin (BCG) vaccination did not alter the progression or viral load of herpetic keratitis in guinea pigs and rabbits. This study found no significant clinical or virological impact from BCG in these animal models of eye infections.
Area of Science:
- Ophthalmology
- Virology
- Immunology
Background:
- Herpetic keratitis, an eye infection caused by Herpesvirus hominis, can lead to significant vision impairment.
- Mycobacterium bovis (Bacillus Calmette-Guérin, BCG) is a widely used vaccine with known immunomodulatory effects.
- The potential impact of BCG on viral infections, particularly ocular infections, requires further investigation.
Purpose of the Study:
- To investigate the effect of Mycobacterium bovis (BCG, Pasteur strain) on the clinical course of herpetic keratitis.
- To determine if BCG influences the viral titer in the corneas of infected animals.
Main Methods:
- Guinea pigs and rabbits were inoculated with Mycobacterium bovis (BCG, Pasteur strain) intraperitoneally.
- Animals were subsequently inoculated intracorneally with Herpesvirus hominis.
- Clinical signs of keratitis and viral titers in the cornea were monitored over three-day and nine-day observation periods.
Main Results:
- BCG administration showed no significant effect on the clinical presentation of herpetic keratitis in either species.
- The viral titer within the infected corneas remained unaffected by the prior BCG inoculation.
- No significant difference was observed in the disease course or viral load between BCG-treated and control groups.
Conclusions:
- Pre-treatment with Mycobacterium bovis (BCG, Pasteur strain) does not significantly alter the clinical outcome or viral replication in experimental herpetic keratitis in guinea pigs and rabbits.
- BCG's immunomodulatory effects do not appear to confer protection or exacerbate Herpesvirus hominis keratitis in these models.
- Further research is needed to explore BCG's role in other viral ocular infections or different stages of herpetic disease.